Fapon to Showcase Innovative Local Manufacturing Solutions at MEDICA 2026 in Düsseldorf, Germany
Fapon to Showcase Local Manufacturing Innovations at MEDICA 2026
Düsseldorf, Germany – Fapon, a globally recognized leader in the life sciences sector, is set to exhibit at the much-anticipated MEDICA 2026 conference from November 16 to 19. This year, the company will emphasize its Local Manufacturing Solutions and comprehensive in vitro diagnostic (IVD) portfolios, aimed at enhancing the local production capabilities of diagnostic manufacturers around the globe.
Fapon has a robust commitment to supporting customers in IVD manufacturing through a complete chain of technology transfer, integrated diagnostics solutions, and a reliable supply of essential raw materials. With a solid foundation of technological expertise and extensive industry experience, Fapon aims to empower its partners to adapt effectively to the dynamic demands of regional markets.
During the exhibition, Fapon will spotlight a variety of Local Manufacturing Solutions that encompass numerous diagnostic methodologies, including chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), clinical biochemistry, point-of-care testing (POCT), and molecular diagnostics (MDx). The company adopts flexible collaboration models that offer comprehensive support in technology transfer and localization. This includes providing core raw materials, bulk reagents, custom development, and manufacturing registration.
A key aspect of Fapon's offerings is assisting partners as they evolve their local IVD manufacturing capabilities—transforming ideas from mere assay development into actionable, locally produced commercial products. Furthermore, Fapon's one-stop IVD solutions integrate raw materials with reagent services and open-system instruments, thereby streamlining diagnostic product development.
A noteworthy highlight of Fapon's innovative capabilities is their blood-based testing solution for Alzheimer's disease (AD), which will also feature at the event. This solution includes essential raw materials and bulk reagents critical for detecting key biomarkers associated with AD, such as p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. This integrated approach not only bolsters product development but also enhances the overall diagnostic landscape.
In addition, Fapon will present its recombinant quality control (QC) materials, designed to ensure consistent assay performance while minimizing supply variability and biosafety risks inherent in natural-source materials. Production evaluation data demonstrates impressive correlation metrics, enhancing trust in their materials. Fapon's production capabilities can accommodate batches of various sizes, thereby ensuring a dependable supply that meets customer demands.
With a legacy of 25 years in the IVD industry, boasting over 1,400 patent applications and partnerships extending to 70 countries across the globe, Fapon continues to spur innovation in diagnostics. Their integrated technological capabilities and a product portfolio that emphasizes localization reflect their commitment to accelerating diagnostic development and amplifying local manufacturing competencies.
Visitors are encouraged to visit Fapon’s booth at Hall 3, Booth D95, during MEDICA 2026 to engage with the team, discuss collaboration prospects, and discover more about their IVD solutions and services.
As a pioneering organization, Fapon is redefining the research and development landscape in diagnostics and therapeutics with an advanced model that combines AI-driven methodologies with systematic experimentation. This approach not only expedites the discovery of novel biomarkers but also smooths the path for precision medicine development.
To learn more about Fapon's initiatives and to schedule meetings during the event, potential partners can follow Fapon on LinkedIn or visit their website.
For any inquiries before or during MEDICA 2026, interested parties can reach out via [email protected]